Trifluridine
Trifluridine has been studied in 2 papers since 2024: 1 observational study in people, 1 in animals; 1 in the past year. The newest paper, Dec 3, 2025: “The crosstalk between ubiquitination and GlcNAcylation of CHAF1A regulates HIV-1 latency and reactivation”.
See all 2 papers on trifluridine
At a glance
The findings reach mice, none yet in people. 2 independent labs in 2 countries; 26 trials, none about aging, 1 with no results posted.
None of its findings points the other way.
- 2 independent labs in 2 countries
- 26 trials, none about aging, 1 with no results posted
- Funders: Agence Nationale de la Recherche and 8 more
- Humans1
- Animals1
What did studies of trifluridine find?
5Studies of trifluridine measured 5 outcomes, among them CHAF1A, HIV-1 latency and clinical signs of progeria.
CHAF1A
downin human cells1
1 study
CHAF1A
downin human cells1
Trifluridine decreases CHAF1A in human cells.
“trifluridine, a Food and Drug Administration-approved antiviral drug, reactivates latent HIV-1 by disrupting O-GlcNAcylation, triggering CHAF1A ubiquitination and proteasomal degradation.”
Cells
Journal of virology
HIV-1 latency
downin human cells1
1 study
HIV-1 latency
downin human cells1
Trifluridine inhibits HIV-1 latency in human cells.
“We identify trifluridine as a novel LRA capable of disrupting O-GlcNAcylation to degrade CHAF1A, thereby effectively reversing latency in primary cells.”
Cellsprimary cells
Journal of virology
Clinical signs of progeria
downin mice1
1 study
Clinical signs of progeria
downin mice1
Trifluridine decreases clinical signs of progeria in a mouse model of HGPS.
“trifluridine treatment in vivo was able to alleviate aortic VSMCs loss and clinical sign of progeria”
Animalsin a mouse model of HGPS
Cell death & disease
Aortic VSMC loss
downin mice1
1 study
Aortic VSMC loss
downin mice1
Trifluridine decreases aortic VSMC loss in a mouse model of HGPS.
“trifluridine treatment in vivo was able to alleviate aortic VSMCs loss and clinical sign of progeria”
Animalsin a mouse model of HGPSaorta
Cell death & disease
NAD+
upin human cells1
1 study
NAD+
upin human cells1
Trifluridine increases NAD+ in human cells (VSMCs differentiated from HGPS patient iPSCs, via decreased PARP-1 activity).
“we identified a new compound, trifluridine able to increase NAD+ levels through decrease of PARP-1 activity.”
CellsVSMCs differentiated from HGPS patient iPSCs, via decreased PARP-1 activityvascular smooth muscle cell
Cell death & disease
Who is developing trifluridine?
3 companies: EMD Serono Research & Development Institute, AbbVie and Taiho Oncology.
Trial sponsors
Company2 trialsPhase 31,510 people
EMD Serono Research & Development Institute
Company1 trialPhase 31,020 people
Company1 trialPhase 3563 people
Company1 trialPhase 3492 people
Company1 trialPhase 3368 people
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
Company1 trialPhase 3142 people
Company1 trialPhase 2120 people
Company1 trialPhase 2100 people